{"id":1715,"date":"2023-06-25T17:32:51","date_gmt":"2023-06-25T17:32:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/celecoxib\/"},"modified":"2023-06-25T19:41:17","modified_gmt":"2023-06-25T19:41:17","slug":"celecoxib","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/celecoxib\/","title":{"rendered":"Celecoxib"},"content":{"rendered":"

<\/p>\n

Celecoxib<\/h1>\n

CLINICAL USE<\/h3>\n

Cox 2 inhibitor and analgesic<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

200 mg once or twice daily<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           :381.4<\/li>\n
  • %Protein binding                           :97<\/li>\n
  • %Excreted unchanged in urine     : <3<\/li>\n
  • Volume of distribution (L\/kg)       :400 litres<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :8\u201312\/Unchanged
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n

    30\u201350 Dose as in normal renal function. Use with caution10\u201330 Dose as in normal renal function, but avoid if possible<\/li>\n

  • <10           : Dose as in normal renal function, but only use if on dialysis
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function<\/li>\n
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   :Unknown dialysability. Dose as in normal renal function<\/li>\n
  • CAV\/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia<\/li>\n
  • Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage)<\/li>\n
  • Antibacterials: possibly increased risk of convulsions with quinolones<\/li>\n
  • Anticoagulants: effects of coumarins enhanced; possibly increased risk of bleeding with heparins and coumarins<\/li>\n
  • Antidepressants: increased risk of bleeding with SSRIs and venlafaxine<\/li>\n
  • Antidiabetic agents: effects of sulphonylureas enhanced<\/li>\n
  • Anti-epileptics: possibly increased phenytoin concentration<\/li>\n
  • Antifungals: if used with fluconazole, halve the dose of celecoxib. Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir<\/li>\n
  • Ciclosporin: may potentiate nephrotoxicity Cytotoxic agents: reduced excretion of methotrexate; increased risk of bleeding with erlotinib<\/li>\n
  • Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics<\/li>\n
  • Lithium: excretion decreased Pentoxifylline: possibly increased risk of bleeding<\/li>\n
  • Tacrolimus: increased risk of nephrotoxicity
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • Clinical trials have shown renal effects similar to those observed with comparative NSAIDs.<\/li>\n
  • Monitor patient for deterioration in renal function and fluid retention<\/li>\n
  • Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease.<\/li>\n
  • Avoid if possible; if not, check serum creatinine 48\u201372 hours after starting NSAID.<\/li>\n
  • If raised, discontinue NSAID therapy<\/li>\n
  • Use normal doses in patients with ERF on dialysis if they do not pass any urine. Use with caution in renal transplant recipients \u2013 can reduce intrarenal autocoid synthesis<\/li>\n
  • Celecoxib should be used with caution in uraemic patients predisposed to gastrointestinal bleeding or uraemic coagulopathies<\/li>\n
  • Contraindicated in patients with ischaemic heart disease or cerebrovascular disease and class II\u2013IV NYHA congestive heart failure.<\/li>\n","protected":false},"excerpt":{"rendered":"

    Celecoxib CLINICAL USE Cox 2 inhibitor and analgesic DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1715","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1715"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1715\/revisions"}],"predecessor-version":[{"id":2834,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1715\/revisions\/2834"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}